常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-13.42/-4.18
|
|
企业价值
280.60M
|
| 资产负债 |
|
每股账面净值
5.05
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
441.00K
|
|
每股收益
0.94
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/15 21:15 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). |

15.11 
